Growth Hormone Axis Protocol

Pulsatile GH-axis stimulation research

Overview

CJC-1295 (No DAC) + Ipamorelin at the standard 2:1 research ratio. Two-receptor secretagogue stack for pulsatile GH-axis research.

What's in This Stack

Each compound ships individually with its own Certificate of Analysis.

  • CJC-1295 NO DAC (Mod GRF 1-29) 5mg — Mod GRF 1-29 — the tetra-substituted GHRH analogue that produces discrete physiological GH pulses without the sustained elevation of DAC, ideal for pulsatile GH research protocols. — $24.99 USD
  • Ipamorelin 5mg — The cleanest GH secretagogue — a selective GHS-R1a agonist producing robust, dose-dependent GH pulses without cortisol elevation, HPA activation, or appetite stimulation. — $43.00 USD

Research Rationale

GH secretion is pulsatile by design — chronic elevation through exogenous somatropin desensitizes the axis and disrupts feedback loops. The CJC-1295 + Ipamorelin combination preserves pulsatility because both peptides have short receptor occupancy windows (CJC-1295 No-DAC ~30 min, Ipamorelin ~2 hr). Hitting the somatotroph through two distinct receptors (GHRH-R and GHSR) produces a larger pulse than either compound alone.

Synergistic Mechanism

The two peptides are most often dosed together at a 2:1 ratio (CJC-1295 No-DAC : Ipamorelin) based on receptor pharmacology. Ipamorelin is highly selective for the ghrelin receptor and notably does not stimulate cortisol or prolactin like older GHRPs. CJC-1295 No-DAC is the modified GRF(1-29) sequence engineered to resist DPP-IV degradation. Their pharmacokinetics align for a clean coordinated GH pulse.

Protocol Details

Components
CJC-1295 No DAC / Mod-GRF (5mg) + Ipamorelin (5mg)
Storage
Lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days
Verification
Each compound independently HPLC verified ≥98% purity
Documentation
Individual COA for each compound included

Key References

  1. Selective GH-releasing properties of Ipamorelin in rat models — Raun et al., 1998
  2. Mod-GRF(1-29) pharmacokinetics and DPP-IV resistance — Teichman et al., 2006
  3. Synergistic GH release with GHRH analog + ghrelin mimetic combinations — Bowers et al., 2002
  4. Ipamorelin selectivity vs. GHRP-2/GHRP-6 — cortisol and prolactin profile — Andersen et al., 2001

Frequently Asked Questions

Why CJC-1295 No DAC instead of CJC-1295 with DAC?
The No-DAC version (also called Mod-GRF 1-29) preserves pulsatility because of its short half-life. The DAC version binds plasma albumin and produces a sustained elevated GH baseline — useful for different research questions, but loses the pulse architecture this stack is designed for.
What is the standard research ratio?
Most published protocols use 2:1 by mass (e.g., 100µg CJC-1295 No-DAC : 50µg Ipamorelin) for in-vitro and animal-model work. The ratio reflects the relative potency of the two compounds at their respective receptors.
Does Ipamorelin raise cortisol or prolactin?
In published primate and human studies (Raun 1998, Sigalos 2018), Ipamorelin is one of the few ghrelin-receptor agonists that does NOT meaningfully elevate cortisol or prolactin at GH-stimulating doses — distinguishing it from GHRP-2 and GHRP-6.